The India malaria diagnostics market is poised for steady growth, with its value projected to increase from US$ 61.6 million in 2025 to US$ 81.6 million by 2032, registering a compound annual growth rate (CAGR) of 4.1% during the forecast period. Historical data from 2019 to 2024 showed a CAGR of 3.3%, indicating a progressive acceleration in market performance.
This growth is being significantly fueled by synergistic initiatives between the Indian government, international health organizations, and private healthcare players. Programs like the National Strategic Plan for Malaria Elimination have enhanced access to reliable diagnostic tools, especially in endemic regions. Partnerships with companies providing cost-effective diagnostic solutions and financial and technical assistance from global entities like the WHO and The Global Fund are further strengthening diagnostic infrastructure and capacity across the country.
Key Industry Highlights
The increasing adoption of molecular diagnostics, including PCR and RT-qPCR technologies, especially in urban centers and tertiary care facilities, marks a key trend in the Indian malaria diagnostics market.
Companies are innovating to detect low-parasitemia and asymptomatic infections, with particular focus on low-endemic zones.
Rapid Diagnostic Tests (RDTs) are anticipated to account for 54.2% of the market in 2025 due to their high-speed detection capabilities, even in remote regions.
Persistent malaria transmission in tribal and forest zones in East India maintains strong demand for RDTs and molecular diagnostics.
Hospitals and clinics are critical distribution nodes for diagnostics and play an essential role in disease surveillance through structured case reporting.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35426
Market Dynamics
Driver – Government Interventions and Technological Innovations Accelerate Detection
India’s rural and tribal regions lack adequate healthcare infrastructure, exacerbating challenges in malaria diagnosis. Approximately 95% of the population lives in malaria-endemic areas, and 80% of the reported cases are concentrated in hilly and forested regions. In these regions, healthcare access and timely diagnosis remain significant bottlenecks. To overcome this, government agencies have ramped up the distribution of RDT kits and Long-Lasting Insecticidal Nets (LLINs) while enhancing community surveillance.
For instance, in Odisha, over 40.49 lakh LLINs were distributed alongside diagnostic kits to support the state’s malaria response efforts. Moreover, innovations such as MAIScope, a portable AI-powered microscope, are being deployed to enable accurate diagnosis in hard-to-reach regions.
Restraint – Diagnostic Gaps in Microscopy Technology
Despite being considered a gold standard, microscopy has struggled in detecting low-density or asymptomatic malaria infections, which are common in India’s low-endemic zones. Detection thresholds typically range from 50–100 parasites/µL, far less sensitive than PCR, which detects as few as 0.01 parasites/µL. This diagnostic gap means many submicroscopic cases remain undiagnosed, leading to sustained transmission and hindering the country’s malaria elimination goals.
Additionally, microscopy’s effectiveness in identifying mixed infections, such as P. vivax and P. falciparum, is limited. Studies show detection accuracy in such cases can be as low as 45%, complicating proper treatment pathways and increasing the likelihood of drug resistance.
Opportunity – Genomic Surveillance Boosts Targeted Malaria Management
The introduction of Next-Generation Sequencing (NGS) is revolutionizing malaria diagnostics in India. High-resolution genomic data enables researchers to detect and track drug-resistant strains across various regions. For example, a recent NGS study on P. falciparum isolates in Rourkela, Chennai, and Nadiad identified region-specific mutations in drug-resistance genes like Pfcrt and Pfdhfr, providing crucial insights into local epidemiology.
Collaborative efforts, such as the India ICEMR initiative, are also employing genomic tools to advance understanding of parasite evolution, enabling targeted treatment protocols and more robust public health responses.
Category-wise Analysis
Technology Insights
The India malaria diagnostics market is segmented into microscopy, Rapid Diagnostic Tests (RDTs), and molecular diagnostics. Among these, RDTs are expected to dominate the market with a projected 54.2% share in 2025, largely due to their portability, cost-efficiency, and rapid results without the need for complex lab infrastructure. RDTs are particularly vital in malaria-prone states such as Odisha, Assam, and Jharkhand, where remote testing is essential.
Conversely, molecular diagnostics, particularly PCR-based methods, are projected to see the highest growth rate owing to their unmatched sensitivity. These are especially useful for detecting submicroscopic and asymptomatic infections, which are instrumental in sustaining malaria transmission in low-endemic areas.
End-use Insights
The market is segmented by end-use into hospitals and clinics, diagnostic centers, and academic and research institutions. In 2025, hospitals and clinics are forecast to hold a 45.6% market share, bolstered by their pivotal role in managing severe malaria cases and integrating rapid testing into treatment protocols.
Meanwhile, diagnostic centers are gaining prominence due to their access to advanced testing tools and ability to deliver comprehensive malaria diagnostics. These centers are particularly impactful in urban and semi-urban locations, where centralized testing helps with early detection and control of outbreaks.
Regional Insights
East India
States like Odisha, Jharkhand, Meghalaya, and Assam continue to be malaria hotspots due to favorable climatic and ecological conditions for vector proliferation. Odisha alone recorded around 42,000 malaria cases in 2023, accounting for 18.7% of the national total. Initiatives such as DAMaN have intensified diagnostics deployment in remote areas. Despite the wide usage of microscopy, sensitivity levels remain low (42.7%), emphasizing the need for broader adoption of molecular diagnostics in this region.
North India
Regions like Punjab and Haryana have shown significant reductions in reported malaria cases, thanks to improved surveillance. However, traditional diagnostics are missing a substantial share of submicroscopic infections—23.4% as per recent studies comparing microscopy and PCR methods. The inefficiency of paper-based reporting and poor integration of private sector data are key weaknesses in North India’s malaria surveillance system, limiting the effectiveness of disease control programs.
West India
States including Goa, Rajasthan, Maharashtra, and Gujarat are witnessing a hybrid diagnostic landscape combining rural outreach and modern lab-based testing. For example, Gujarat’s public health centers offer free blood smear examinations, but delays in results often lead to presumptive treatments. To counter this, RDTs are being adopted for faster diagnosis and more accurate treatment initiation. Urban centers are also increasingly incorporating RDTs into their malaria management frameworks.
Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35426
Competitive Landscape
India’s malaria diagnostics market comprises a mix of multinational corporations, domestic diagnostic companies, and emerging biotech firms. Global leaders like Bio-Rad, Abbott, Hologic, and Roche Diagnostics are expanding their product portfolios and customizing solutions for Indian conditions. These companies are also investing in scalable molecular technologies to meet evolving healthcare needs.
Local manufacturers like MicroGene Diagnostic Systems and Premier Medical Corporation are playing a vital role in ensuring affordability and availability, especially in rural markets. These companies are focused on producing high-quality RDTs and microscopy tools tailored to Indian climatic and logistical challenges.
Key Players
Bio-Rad Laboratories Inc.
Access Bio Inc.
Abbott India Limited
Hologic, Inc.
Roche Diagnostics India Pvt. Ltd.
Sysmex India Private Limited
Becton Dickinson India Private Limited
Siemens Healthineers AG
Meridian Bioscience, Inc.
Olympus Corporation
Nikon India Pvt Ltd
Beckman Coulter, Inc.
MicroGene Diagnostic Systems (P) Ltd
Premier Medical
Market Segmentation
By Technology:
Microscopy
Rapid Diagnostic Tests (RDTs)
Molecular Diagnostic Tests (PCR, RT-qPCR)
By End-use:
Hospitals and Clinics
Diagnostic Centers
Academic and Research Institutions
By Region:
East India
North India
West India
South India (data not covered but assumed for full segmentation)
Recent Developments
In April 2025, officials from the National Vector Borne Disease Control Program (NVBDCP) under the National Health Mission (NHM) emphasized the importance of source reduction as a key strategy to eradicate malaria, especially in Mizoram, which continues to report the highest API nationwide.
In May 2024, Serum Institute of India shipped its first batch of the R21/Matrix-M malaria vaccine to African nations, including CAR and South Sudan. Though primarily aimed at African markets, this move underscores India’s growing expertise in malaria-related biotech innovations.
Future Outlook
India’s malaria diagnostics market is projected to experience sustained growth through 2032, driven by government backing, technology adoption, and private sector innovation. While RDTs will remain dominant due to their scalability, molecular diagnostics are set to emerge as the future of accurate detection, especially in the context of malaria elimination goals.
